{
  "timestamp": "20250104_050235",
  "model": "gpt-4-turbo",
  "interaction_type": "answer_with_CoT",
  "question_id": "40003db8",
  "question_text": "Anticoagulant of choice for prophylaxis of venous thromboembolism in patient with cancer surgery is:-",
  "messages": [
    {
      "role": "system",
      "content": "You are a medical expert using chain-of-thought reasoning."
    },
    {
      "role": "user",
      "content": "You are a medical expert specializing in the field of Pharmacology.\n            You are a medical expert determining the final answer.\n\n                ### Instructions:\n                - Use standard medical knowledge as the primary guide.\n                - Consider enhanced information only if it aligns with consensus.\n                - If conflicting or unclear, present the most likely correct answer based on known facts.\n                - It's acceptable to show moderate confidence if the question is complex, but still choose one best answer.\n            ### Question    \n            Anticoagulant of choice for prophylaxis of venous thromboembolism in patient with cancer surgery is:-\n\n            ### Options\n            opa. Heparin sulfate\nopb. Protamine sulfate\nopc. Low molecular weight heparin\nopd. Warfarin\n\n### Reasoning Chains for Validation:\n- CHAIN: \"Cancer surgery\" -> \"increased risk of venous thromboembolism\" -> \"need for effective anticoagulant\" -> \"Low molecular weight heparin\" -> \"proven efficacy in cancer patients\" -> \"recommended by guidelines\" -> 95%\n- CHAIN: \"Cancer surgery\" -> \"increased risk of venous thromboembolism\" -> \"need for anticoagulation\" -> \"Heparin sulfate\" -> \"less effective in cancer patients compared to LMWH\" -> \"not the first choice\" -> 70%\n- CHAIN: \"Cancer surgery\" -> \"increased risk of venous thromboembolism\" -> \"need for anticoagulation\" -> \"Warfarin\" -> \"requires monitoring and slow onset\" -> \"not ideal for immediate postoperative period\" -> 65%\n- CHAIN: \"Cancer surgery\" -> \"increased risk of venous thromboembolism\" -> \"need for anticoagulation\" -> \"Protamine sulfate\" -> \"used to reverse effects of heparin, not as a prophylactic\" -> \"incorrect use\" -> 10%\n\n### Retrieved Validation Paths:\n- (Venous Thromboembolism)-CAUSES->(Death, Sudden)-ASSOCIATED_WITH->(Genes)-INTERACTS_WITH->(Anticoagulants)\n- (anticoagulation)-CAUSES/PREVENTS->(Disease)-MANIFESTATION_OF->(Antiinflammatory Effect)-ASSOCIATED_WITH->(Protamine Sulfate)\n- (anticoagulation)-CAUSES/PREVENTS->(Thrombosis)-ASSOCIATED_WITH->(Warfarin)\n- (Venous Thromboembolism)-CAUSES->(Shock)-ASSOCIATED_WITH->(Genes)-INTERACTS_WITH->(Anticoagulants)\n- (Protamine Sulfate)-INTERACTS_WITH->(Embryonic Stem Cell)-PART_OF->(Column)-LOCATION_OF->(Condoms, Male)\n\n            ### Task:\n                1. Identify the core medical principle and the most likely correct option based on consensus.\n                2. If the evidence is not perfectly clear, pick the best-supported option and explain the reasoning.\n                3. Provide a final analysis and a confidence score (0-100%).\n                \n                ### Output Format:\n                {\n                  \"final_analysis\": \"Step-by-step reasoning, prioritizing medical consensus and acknowledging complexity if present.\",\n                  \"answer\": \"Option key (e.g. opa, opb, ...)\",\n                  \"confidence\": A number between 0-100\n                }\n            "
    }
  ],
  "response": "### Core Medical Principle:\nThe primary goal in the management of patients undergoing cancer surgery is to prevent venous thromboembolism (VTE), which is a common and potentially fatal complication. The choice of anticoagulant is crucial for effective prophylaxis.\n\n### Analysis of Options:\n- **Heparin sulfate (opa)**: While heparin is a standard anticoagulant, it is generally less favored in cancer patients due to its pharmacokinetic properties and the need for frequent monitoring.\n  \n- **Protamine sulfate (opb)**: This is used to reverse the effects of heparin and is not an anticoagulant for prophylaxis purposes.\n\n- **Low molecular weight heparin (LMWH) (opc)**: LMWH, such as enoxaparin, is widely recommended for thromboprophylaxis in cancer patients. It has been shown to be effective and safe, with a lower risk of bleeding compared to other anticoagulants and does not require routine laboratory monitoring. It is specifically endorsed in various clinical guidelines for cancer-associated thrombosis.\n\n- **Warfarin (opd)**: Warfarin is effective for long-term anticoagulation but is less ideal for immediate postoperative prophylaxis due to its need for careful monitoring of the INR (International Normalized Ratio), dietary restrictions, and drug interactions. Its onset of action is also slower.\n\n### Final Analysis:\nConsidering the specific needs of patients undergoing cancer surgery, low molecular weight heparin (LMWH) is the most appropriate choice for prophylaxis of venous thromboembolism. It aligns with clinical guidelines and has a strong evidence base supporting its use in this particular patient population. LMWH offers a balance of efficacy, safety, and ease of use, which is crucial in the immediate postoperative period.\n\nGiven the consensus in clinical practice and guidelines, the best-supported option is low molecular weight heparin.\n\n```json\n{\n  \"final_analysis\": \"Low molecular weight heparin is recommended for VTE prophylaxis in cancer surgery patients due to its proven efficacy, safety profile, and ease of use without the need for routine monitoring, aligning with clinical guidelines.\",\n  \"answer\": \"opc\",\n  \"confidence\": 95\n}\n```",
  "metadata": {
    "topic": "Pharmacology",
    "is_multi_choice": true,
    "has_reasoning_chain": true,
    "has_enhanced_info": true,
    "model_config": "gpt-4-turbo",
    "temperature": 0.0
  }
}